Pasqualetti, Francesco <br/><br/>
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.  [electronic resource] 

 -  American journal of clinical oncology  12 2018 
 - 1272-1275 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1537-453X 
<br/><br/><label>Standard No.: </label>10.1097/COC.0000000000000464  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Bevacizumab--therapeutic use<br/>Brain Neoplasms--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Glioblastoma--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Nitrosourea Compounds--pharmacology<br/>Organophosphorus Compounds--pharmacology<br/>Prognosis<br/>Retrospective Studies<br/>Salvage Therapy<br/>Survival Rate<br/>Young Adult